Show simple item record

dc.contributor.authorOkafor, Chukwuka C
dc.contributor.authorPerreault-Micale, Cynthia
dc.contributor.authorHajjar, Roger J
dc.contributor.authorLebeche, Djamel
dc.contributor.authorSkiroman, Klara
dc.contributor.authorJabbour, George
dc.contributor.authorDoye, Angelia A
dc.contributor.authorLee, Michael X.
dc.contributor.authorLaste, Nancy
dc.contributor.authorGwathmey, Judith Karen
dc.date.accessioned2013-01-24T18:36:29Z
dc.date.issued2003
dc.identifier.citationOkafor, Chukwuka C., Cynthia Perreault-Micale, Roger J. Hajjar, Djamel Lebeche, Klara Skiroman, George Jabbour, Angelia A. Doye, Michael X. Lee, Nancy Laste, and Judith K. Gwathmey. 2003. Chronic treatment with Carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. BMC Physiology 3:6.en_US
dc.identifier.issn1472-6793en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:10219388
dc.description.abstractBackground: \(\beta\)-blocker treatment has emerged as an effective treatment modality for heart failure. Interestingly, \(\beta\)-blockers can activate both pro-apoptotic and anti-apoptotic pathways. Nevertheless, the mechanism for improved cardiac function seen with \(\beta\)-blocker treatment remains largely unknown. Carvedilol is a non-selective \(\beta\)-blocker with \(\alpha\)-receptor blockade and antioxidant properties. We therefore studied the impact of the effects of carvedilol in an animal model of end-stage heart failure. Results: To test whether chronic treatment with \(\beta\)-blockade decreases apoptosis, we treated myopathic turkeys with two dosages of carvedilol, 1 mg/kg (\(DCM_1\)) and 20 mg/kg (\(DCM_{20}\)), for four weeks and compared them to non-treated DCM animals (\(DCM_0\)) and to control turkeys (CON). Echocardiographic measurements showed that non-treated DCM animals had a significantly lower fractional shortening (FS) when compared to CON (68.73 \(\pm\) 1.37 vs. 18.76 \(\pm\) 0.59%, p < 0.001). Both doses of carvedilol significantly improved FS (33.83 \(\pm\) 10.11 and 27.73 \(\pm\) 6.18% vs. 18.76 \(\pm\) 0.59 % for untreated DCM, p < 0.001). DCM left ventricles were characterized by a higher percentage of apoptotic nuclei when compared to CON (5.64 \(\pm\) 0.49 vs. 1.72 \(\pm\) 0.12%, respectively p < 0.001). Both doses of carvedilol significantly reduced the number of apoptotic nuclei (2.32 \(\pm\) 0.23% and 2.36 \(\pm\) 0.26% 1 mg and 20 mg/kg respectively). Conclusions: Carvedilol improves ventricular function. Furthermore, treatment with carvedilol decreased the incidence of apoptosis in cardiac myocytes from failing hearts at both doses. These data suggest that the inhibition of apoptosis with carvedilol may lead to improvement in ventricular function and may underlie a beneficial effect of \(\beta\)-blockade independent of heart rate lowering effects.en_US
dc.language.isoen_USen_US
dc.publisherBioMed Centralen_US
dc.relation.isversionofdoi://10.1186/1472-6793-3-6en_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC212709/pdf/en_US
dc.relation.hasversionhttp://www.biomedcentral.com/1472-6793/3/6en_US
dash.licenseLAA
dc.titleChronic Treatment with Carvedilol Improves Ventricular Function and Reduces Myocyte Apoptosis in an Animal Model of Heart Failureen_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalBMC Physiologyen_US
dash.depositing.authorGwathmey, Judith Karen
dc.date.available2013-01-24T18:36:29Z
dash.affiliation.otherHMS^Medicine- Beth Israel-Deaconessen_US
dc.identifier.doi10.1186/1472-6793-3-6*
dash.contributor.affiliatedGwathmey, Judith Karen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record